Abstract: A PEG-lipid is produced by mixing a cation-PEG-lipid comprising at least one amino group with a sulfated glycosaminoglycan comprising at least one carbonyl group to form a Schiff base intermediate. A reducing agent is added to the Schiff base intermediate to form a sulfated glycosaminoglycan-PEG-lipid. The sulfated glycosaminoglycan-PEG-lipid can be used to biological tissue against thromboinflammation. Coating of biological tissue with the sulfated glycosaminoglycan-PEG-lipid can be done in a single step process and does not cause any significant cell aggregation.

Abstract: The present invention is intended to provide a peptide that selectively binds to a metal surface. Specifically, the present invention relates to a peptide consisting of an amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8, or a peptide substantially identical to the aforementioned peptide, and a method for detecting a metal surface of a medical device, using these peptides.

Abstract: An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammation and reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient.

Abstract: The present invention is intended to provide a peptide that selectively binds to a metal surface. The present invention relates to a peptide consisting of an amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 21, or a peptide substantially identical to the aforementioned peptide, and a method for detecting a metal surface of a medical device, using these peptides.

Abstract: The present invention provides an agent containing L-tyrosine that prevents methemoglobin formation, and a vesicle comprising the above agent for preventing methemoglobin formation. More specifically, the present invention provides an oxygen infusion preparation suitable for long-term storage, which prevents an increase in methemoglobin content as a result of oxidation of hemoglobin or the like encapsulated in an vesicle having a lipid bilayer membrane structure.

Abstract: An oxygen carrier system includes an artificial oxygen carrier including hemoglobin vesicles encapsulating hemoglobin and an intermediate electron mediator having a standard electrode potential of 0.05 V to 0.56 V (vs. the standard hydrogen electrode) in the vesicles, and a reducing agent which is added to an external aqueous phase of the hemoglobin vesicle to reduce methemoglobin when the hemoglobin encapsulated in the hemoglobin vesicle is oxidized to the methemoglobin. The reducing agent has, as an active component, at least one compound selected from the group consisting of a thiol compound and a reducing sugar.

Abstract: An oxygen carrier system includes an artificial oxygen carrier including hemoglobin vesicles encapsulating hemoglobin and an intermediate electron mediator having a standard electrode potential of 0.05 V to 0.56 V (vs. the standard hydrogen electrode) in the vesicles, and a reducing agent which is added to an external aqueous phase of the hemoglobin vesicle to reduce methemoglobin when the hemoglobin encapsulated in the hemoglobin vesicle is oxidized to the methemoglobin. The reducing agent has, as an active component, at least one compound selected from the group consisting of a thiol compound and a reducing sugar.

Abstract: An image forming apparatus includes a plurality of image bearing components and a plurality of image writing units for writing an image on each of the image bearing components. The apparatus also includes a frame for supporting the plurality of the image bearing components and the plurality of image writing units. The frame has a plurality a of first holding parts for holding both ends of each of the image bearing components and a plurality of second holding parts for holding both ends of each of the image writing units.

Abstract: In a conventional color printer, especially an in-line type full color image forming apparatus, an aberration of optical axes caused by distortions of structures affect a performance of an image forming as a tilt aberration in a printed image. Accordingly, in a conventional color printer, distortions have to be prevented by strengthening rigidity of machine structures or parts of the machine. However, fine adjustment or assembling to strengthen rigidity generally causes an increase in cost and requires time-consuming adjustment. An apparatus in the present invention provides advantages of high accuracy and strengthened structure without increasing cost.